Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

1.1K
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
1.1K
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

1.0K
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
1.0K
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

541
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
541
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

755
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
755
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

632
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
632
Necrosis01:16

Necrosis

6.6K
Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
6.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-World Effectiveness and Safety of Upadacitinib in Crohn's Disease: Insights From the Eneida Registry.

United European gastroenterology journal·2026
Same author

Adequacy of pharmacological prescription in patients at very high risk of fracture within the FLS in Spain: analysis of the REFRA FLS-SEIOMM Registry.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2025
Same author

Treatment patterns and intensification within 5 year of follow-up of the first-line anti-TNFα used for the treatment of IBD: Results from the VERNE study.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2021
Same author

Incidence, morbidity and mortality of hip fractures over a period of 20 years in a health area of Southern Spain.

BMJ open·2020
Same author

Prevalence and Factors Associated With Fatigue in Patients With Inflammatory Bowel Disease: A Multicentre Study.

Journal of Crohn's & colitis·2019
Same author

A dynamically young and perturbed Milky Way disk.

Nature·2018
Same journal

Comparison of adenoma and gland hyperplasia on bone mineral density in primary hyperparathyroidism.

Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry·2026
Same journal

The influence of pregnancy and selected aspects of female health on skeletal status and fracture incidence in postmenopausal women from the RACOST-POL Study.

Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry·2026
Same journal

The association of sclerostin with osteoporosis and vertebral fractures in patients with type 2 diabetes mellitus.

Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry·2026
Same journal

Assessment of bone microarchitecture in postmenopausal women with primary hyperparathyroidism using trabecular bone score.

Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry·2026
Same journal

Erxian decoction for postmenopausal osteoporosis: An updated systematic review and meta-analysis.

Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry·2026
Same journal

Associations of discordance in hip bone mineral density with hip osteoarthrosis severity and progression to total hip replacement in middle-aged adults.

Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry·2026
See all related articles

Related Experiment Video

Updated: Feb 5, 2026

Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease
08:27

Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease

Published on: September 20, 2018

8.1K

Does the Antitumor Necrosis Factor-α Therapy Decrease the Vertebral Fractures Occurrence in Inflammatory Bowel

M B Maldonado-Pérez1, L Castro-Laria1, A Caunedo-Álvarez2

  • 1Department of Gastroenterology, University Hospital Virgen Macarena, Seville, Spain.

Journal of Clinical Densitometry : the Official Journal of the International Society for Clinical Densitometry
|September 13, 2018
PubMed
Summary
This summary is machine-generated.

Anti-tumor necrosis factor (TNF)-α therapy increased bone density in inflammatory bowel disease (IBD) patients but did not lower fracture risk. Previous fractures were the main predictor of future fractures in IBD.

Keywords:
Vertebral fracturesanti-TNF-α therapybone mineral densitybone remodelinginflammatory bowel disease

More Related Videos

DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat
09:04

DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat

Published on: February 27, 2014

49.0K
Effects of Taste Signaling Protein Abolishment on Gut Inflammation in an Inflammatory Bowel Disease Mouse Model
09:31

Effects of Taste Signaling Protein Abolishment on Gut Inflammation in an Inflammatory Bowel Disease Mouse Model

Published on: November 9, 2018

9.1K

Related Experiment Videos

Last Updated: Feb 5, 2026

Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease
08:27

Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease

Published on: September 20, 2018

8.1K
DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat
09:04

DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat

Published on: February 27, 2014

49.0K
Effects of Taste Signaling Protein Abolishment on Gut Inflammation in an Inflammatory Bowel Disease Mouse Model
09:31

Effects of Taste Signaling Protein Abolishment on Gut Inflammation in an Inflammatory Bowel Disease Mouse Model

Published on: November 9, 2018

9.1K

Area of Science:

  • Gastroenterology
  • Rheumatology
  • Endocrinology

Background:

  • Osteoporosis and fractures are common extraintestinal manifestations in inflammatory bowel disease (IBD).
  • The role of anti-tumor necrosis factor (TNF)-α therapy in preventing fractures and modifying bone density in IBD patients remains unclear.
  • Etiopathogenic mechanisms linking IBD to bone complications require further elucidation.

Purpose of the Study:

  • To investigate whether anti-tumor necrosis factor (TNF)-α therapy reduces fracture risk in IBD patients.
  • To assess the impact of anti-TNF-α therapy on bone mineral density (BMD) in IBD.
  • To identify risk factors associated with fractures and determine the incidence of vertebral fractures in IBD patients.

Main Methods:

  • A 7-year longitudinal prospective cohort study included 71 IBD patients.
  • Patients were divided into two groups: 23 treated with anti-TNF-α and 48 receiving conventional therapy.
  • Methods included questionnaires for risk factors, dorsolumbar-spine radiographs, bone density measurements, and biochemical/bone remodeling parameter analysis.

Main Results:

  • Anti-TNF-α therapy did not significantly reduce the risk of new vertebral fractures compared to conventional treatment.
  • Patients treated with anti-TNF-α showed a significant increase in bone mass: 8% in the lumbar spine and 6.7% in the femoral neck.
  • A history of previous fractures was the sole significant determinant factor for the incidence of vertebral fractures (OR 12.8, p=0.003).
  • The incidence of vertebral fractures in IBD patients was high, recorded at 26.7 per 700 patient-years.

Conclusions:

  • While anti-TNF-α therapy improves bone mass in IBD patients, it does not decrease the risk of new vertebral fractures.
  • The incidence of fractures is notably high in patients with IBD.
  • Previous vertebral fractures are a strong predictive factor for subsequent fractures in this population.